-
Mashup Score: 10Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial - 9 hour(s) ago
In PARAGLIDE-HF, in patients with ejection fraction (EF) > 40%, stabilized after worsening heart failure (WHF), sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared to valsartan alone, despite more symptomatic hypotension (SH). Concern about SH may be limiting the use of sacubitril/valsartan in appropriate patients.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 21Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events - 1 day(s) ago
The prognosis of individuals with and without an established heart failure (HF) diagnosis and similarly elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels is not well-known.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
📣From the CANVAS trial: In pts with Type 2 DM & CV risk factors, ⬆️ NT-proBNP assoc with ⬆️ HFH and CV death REGARDLESS of baseline HF dx (though ⬆️ risk with baseline HF) 🔗https://t.co/2iKkboSIY7 https://t.co/jKG6bX0FBv
-
-
Mashup Score: 26
Cardiovascular disease (CVD) and heart failure (HF), in particular, impose significant burdens on patients and families. Palliative care (PC)—medical care for patients with serious illness that aims to relieve suffering, enhance quality of life and assist with complex decision-making—is acknowledged by both U.S. and European guidelines to be an integral component of comprehensive HF care. Despite these recommendations, there are well-described gaps in the provision of PC to patients with HF.1 At the same time, there is a growing desire among many HF clinicians, especially those who are in training or early in their careers, to integrate PC more formally into their practices.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
🚨A must-read! Integrating palliative care 🤝🤝 w/ cardiology 🫀 "Supportive Cardiology" This November @JCardFail article outlines: 1) Training pathways to becoming a palliative-trained cardiologist 2) Roles of the palliative cardiologist 🔗https://t.co/Cp3FKD3Xjc https://t.co/4Q08kpmPyi
-
-
Mashup Score: 27Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from the Heart Failure Society of America - 23 day(s) ago
Heart failure (HF) is characterized by significant symptoms, compromised quality of life, frequent hospital admissions, and high mortality; palliative care (PC) is therefore highly relevant for patients with HF and their clinicians. Multiple guidelines and consensus statements recommend the provision of PC alongside HF management. However, few resources exist to guide the integration of PC into HF care, both for primary PC (provided by HF clinicians in the course of HF care) and specialty PC (provided by PC specialists).
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
Palliative Care (PC) is integral to HF care, but there is little info on how it can be incorporated into comprehensive HF care. Check out @HFSA's Consensus Statement on PC in HF for a practical guide for clinicians caring for these complex patients. 🔗https://t.co/wIiQYQgZkx https://t.co/H1f6V91O2d
-
-
Mashup Score: 16Antithrombotic Strategies With Left Ventricular Assist Devices - 24 day(s) ago
Durable left ventricular assist devices (LVADs) are a well-established treatment for advanced heart failure (HF). Their long-term success is primarily due to improved pump designs better adapted to the human blood pool milieu, thereby enhancing “hemocompatibility.”1,2 Technological advances have focused on mitigating complications from the interaction between the pump and blood, such as pump thrombosis, stroke, and bleeding events—collectively termed hemocompatibility-related adverse events (HRAEs).
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
⭐️SOTA alert! Check out this review outlining the current landscape of advances in AC management in LVAD patients! 📌Antithrombotic therapy modifications have paralleled advances in LVAD technology to enhance hemocompatibility-related AE 🔗https://t.co/nFcznyv7zw https://t.co/tnMrc60Z3G
-
-
Mashup Score: 24Ivabradine in Cardiogenic Shock - 29 day(s) ago
Management of patients in cardiogenic shock (CS) relies on limited evidence. Hemodynamic targets, including heart rate, are empirical and vary between institutions. Although some degree of tachycardia may be compensatory, excessive tachycardia can be detrimental. In CS, tachycardia is often exacerbated by vasopressors and inotropes. We hypothesize that mitigating excessive tachycardia may result in prolonging diastole, improvements in diastolic filling, and enhanced subsequent cardiac contraction, thereby eliciting a hemodynamically favorable response.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
Despite best efforts, cardiogenic shock mortality remains unacceptably high. @mguglin proposes an interesting approach in this perspective piece. Can ivabradine, a funny current inhibitor, shift the needle for outcomes in CS due to acute MI? 📷https://t.co/faMvuAbS3x https://t.co/ZcIwDTzGD5
-
-
Mashup Score: 44Going with the Flow: Device therapy for Heart Failure Complicated by Cardiorenal Syndrome - 1 month(s) ago
Cardiorenal syndrome (CRS) affects up to 40% of patients admitted with acute decompensated heart failure (ADHF) [1]. Although the precise mechanisms driving ADHF-CRS at the neurohormonal and cellular levels have not been fully elucidated, is it clear that the syndrome results from complex, multifactorial pathophysiologies, inclusive of reciprocal and unfavorable hemodynamic interactions between the heart and kidneys,[2] along with neurohormonal activation and fibrotic structural changes that contribute to progressive cardio-renal dysfunction and congestion.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
“Pushing & pulling” to fight CRS in acute #HeartFailure. 🫀 In this #JCFIgnite article in press, @LAuroraMD @gfgrafton @preventfailure discuss the latest in med devices to ⬆️ renal perfusion or ⬇️ venous hypertension. 🥊 #THT2024 🔗 https://t.co/P6B0K3iIJz https://t.co/Z2CENkBBSy
-
-
Mashup Score: 23
Amyloid cardiomyopathy is most commonly caused by 1 of 2 precursor proteins: (1) monoclonal immunoglobulin light chain produced in bone-marrow plasma cell disorders; or (2) transthyretin (TTR), also known as prealbumin, a thyroxine and retinol (vitamin A) transport protein produced mainly in the liver. The abbreviations for the associated amyloid cardiomyopathies are termed light-chain cardiac amyloidosis (AL-CA) and transthyretin cardiac amyloidosis (ATTR-CA), respectively. Distinction between these 2 forms of cardiac amyloidosis is critical, because they differ significantly regarding their epidemiology, pathobiology, genetics, outcomes, and treatment (Table 1).
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
🚨Cardio-onc supplement on AL Amyloidosis in HF Understanding these 🔑 points is crucial to help this high-risk population! 🔑 Early recognition before CV dysfunction has ensued 🔑 Early implementation of plasma cell Rx 🔑 HF management 🔗 https://t.co/w81mpoqlZb https://t.co/D5DizMdUgG
-
-
Mashup Score: 41In Memoriam: Aslan Turer, MD, MHS, MBA (1974–2024) - 2 month(s) ago
Dr. Aslan Teyfik Turer, MD, MHS, MBA, passed away in his home following a lengthy illness on May 17, 2024, at the age of 49 years old.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
Dr. Aslan Turer, beloved interventional cardiologist, educator, and leader at @UTSWMedCenter, passed away earlier this year. He is remembered in this heartwarming piece written by friends & colleagues @JTThibs @SKGMDMBA @LannyHallMD 💜 🔗https://t.co/0nE4hTHrW1 https://t.co/yVZ7wlQEPH
-
-
Mashup Score: 19Dual Training in Interventional Cardiology: The Next Frontier - 2 month(s) ago
Dual training in Interventional Cardiology (IC) with other cardiac subspecialties such as Advanced Heart Failure and Transplant Cardiology (AHFTC) and Critical Care Cardiology (CCC) is becoming a pathway for trainees to acquire a needed skill set to deliver comprehensive care for increasingly complex patients in the intensive care unit and catheterization laboratory settings. The makeup of these training pathways varies depending on several factors, with the resultant role of the specialist reflecting this reality.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet-
Interventional Cardiology 🤝 Advanced HF 🤝 Critical Care Check out this ECT Spotlight article that proposes hybrid training pathways for those interested in Interventional Cardiology➕Advanced HF or Critical Care. 🔗 https://t.co/deQRVnKepQ https://t.co/w6UnW2Leuj
-
Which patients with HFmrEF/HFpEF are most likely to develop symptomatic hypotension with ARNI? Risk factors from #PARAGLIDE-HF Trial: ⚪️ LVEF > 60% ⚪️ SBP < 128 mmHg ⚪️ White race ARNI benefit may be greatest in pts with LVEF < 60% and higher SBP 🔗https://t.co/ZE4V0LfVr1 https://t.co/n47hij2R4Q